Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023: One-Stop Source for Providing Real-Deal Information on Hundreds of Transactions

2023-04-07
PRNewswire
疫苗引进/卖出并购
DUBLIN , April 7, 2023 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" report has been added to
ResearchAndMarkets.com's offering.
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Key benefits
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits:
In-depth understanding of royalty rate partnering deal trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes:
Trends in royalty rates in the biopharma industry since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of licensing deals which disclose royalty rates since 2010
Access to licensing contract documents which disclose royalty rates
The leading licensing deals by royalty rate value since 2010
Most active royalty rate disclosures since 2010
In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
Actavis (acquired by Watson)
Active Biomaterials
Adaptimmune
Adlai Nortye
Advanced Dosage Forms
Advaxis
Advirna
AEterna Zentaris
Afritex Medical Products
Alchemia
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alternavida
Altman Enterprises
AltrazealTrading
American Type Culture Collection (ATCC)
Amyris
AnnaMed
Antigen Express
Athenex
Authentic Brands Group
Belgian Volition
Biopharmex
Bioprocess Capital Ventures
BioProspect
Biotech Investment
Biotechnology Value Fund
BMV Medica
Cannus Partners
CB2 Therapeutics
Celyad
Cereal Ingredients
cGreen
Chi-Med
Chiesi Farmaceutici
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Clal Biotech
CMIC
Cohen-McNiece Foundation
Common Sense
Concile
ContraFect
Cures Within Reach
Curis
Daiichi Sankyo
Dance Biopharm
Dermin
Dr. Falk Pharma
Dr. Reddy's Laboratories
Drugs for Neglected Diseases Initiative
Egalet
Elencee
Endocyte
Entest BioMedical
EnWave
Epizyme
Epocal
Evolva
Eyevance
Fairview Health System
FusionVax
Geron
Government of Israel
Gravocore
Hail First Pharma
Health Canada
Health Discovery
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HemoCleanse
Hemogenyx
HemPup
Hoffmann La Roche
Ice + Jam
IDC-GP Pharm
Immunomic
iNAP
Internet Marketing Consortium
Intuitive Surgical
Ipsen
Israeli National Authority for Technological Innovation
John Morley Foods
K2M
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kitov
Klaria
Knighton Foods
KVK-Tech
Kyowa Hakko Kirin
Laboratories Acbel
Level Brands
Lubrizol
Lumenis
Lundbeck
Macrogenics
MainPointe
Marvanal
Marv Enterprises
McEwen Centre for Regenerative Medicine
Meda
Medica Avante
Medical Technologies Innovation Asia
Medicines Patent Pool Foundation
MediGene
MedImmune
Medivation
Melmed
Memory Dx
Merck and Co
Merus
Micromet
Millennium
Mimi's Rock
Labor and Welfare
Morgan Stanley
NantCell
National Green Biomed
Nephrogenex
Nephros
NeuroVive Pharmaceutical Asia
Notable Labs
Novan Therapeutics
Novocure
Nucorion
NutraOrigin
NXTGEN
Oberland Capital
Omeros
Oncologie
Onegevity
One Way Liver Genomics (OWL)
Orgenesis
Orion
Orox Pharmaceuticals
Otsuka
Pan-Provincial Vaccine Enterprise
Pharmastrip
Phosphagenics
Phyto Nutricare
Pieris
Pozen
PreMD
Professional Compounding Centers of America
Prosidion
QRxPharma
Reedy Creek Investments
RegenaStem
Resarci Therapeutics
Retrophin
RST Biomedikal Sanayi
SACCO
Sam Amer
Senetek
Skinvera
Soliance
STADA Arzneimittel
Sucampo AG
Synergy Strips
Tactical Relief
Taiba
TB Alliance
Technion Research and Development Foundation
The Regents of the University of California
Tilray
Titterington Veterinary Services
Tramorgan
Transgene
Trevena
TrovaGene
TTFactor
Uluru
UniQure
Universal Cells
University Health Network
UOP
Uppsalagruppen Medical
ValiPharma
Veracyte
Virbac
Wisconsin Alumni Research Foundation
World Class Extractions
Yeugnam University
Zenitech
For more information about this report visit https://www.researchandmarkets.com/r/4j3g2b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。